Antibody Biologic mRNA

Antibody therapeutics are powerful biologics widely used in the treatment of a multitude of diseases. Conventional antibody biologics rely on in vitro CHO cells for scaled-up production in a certified GMP grade facility and intravenous administration in a closely monitored clinical setting. mRNA is a new and emergent biologic which can be delivered intravenously into the patient and produces the antibody in vivo by utilizing the patient’s liver as a protein production factory.

Abnova’s antibody biologic mRNA service integrates its long-standing antibody expertise, mRNA IVT technology, and powerful lipid nanoparticle (LNP) delivery. This approach allows the in vivo delivery of antibody instructional sequences of the light chain and heavy chain to the liver cells via encapsulated ionizable lipid nanoparticles. The liver cells rapidly produce the complete IgG antibody with proper protein modification and conformation mimicking the natural antibody produced by the plasma cells in a biological host.

With expertise not only in antibody vector design, codon optimization, mRNA modification and purification, Abnova provides an efficient in vivo antibody biologic platform which preclude incompatible protein modification, protracted cell-based manufacturing, and increased production costs. This platform is widely applicable to the growing list of therapeutic antibodies approved by the FDA.